Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT: OvaRex consolidation in ovarian cancer
NCT00050375Phase 3Terminated
- Sponsor
- Unither Pharmaceuticals
- Start
- Dec 2002
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of oregovomab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Unither Pharmaceuticals. Started Dec 2002; status: terminated.
02
Drugs
oregovomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00050375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050375.